A
Description
Israeli pharmaceutical company founded in 2008, focused on CNS disorders. Developed Metadoxine Extended Release (MDX) for ADHD and Fragile X syndrome. Listed on NASDAQ. Merged with Arcturus Therapeutics in 2017.